Current inclusion criteriaSevere HA (FVIII < 1 IU/dL)Severe and moderately severe HB (FIX ≤ 2 IU/dL)Potential for clinical and patient benefitNo history of current or previous inhibitors that required immune tolerance. This evidence concerns the gene F8 and hemoglobin measurement.